NDAORALCAPSULEPriority Review
Approved
Feb 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Receptor Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
Started Mar 2026
87 enrolled
Cervical Cancer by FIGO Stage 2018Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
Started Oct 2025
140 enrolled
Hepatocellular Carcinoma
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Started Aug 2025
114 enrolled
Hepatocellular Carcinoma
Merck IIT: RRP Pembro and Lenvatinib
Started Jul 2025
20 enrolled
Human Papilloma VirusRecurrent Respiratory PapillomatosisPulmonary Disease
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
Started Jun 2025
0Renal Cell CarcinomaBrain Metastasis
Loss of Exclusivity
LOE Date
Nov 15, 2038
154 months away
Patent Expiry
Nov 15, 2038
Exclusivity Expiry
Oct 3, 2027
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7253286 | Oct 24, 2025Expired | SubstanceProduct | — |
| 7253286*PED | Apr 24, 2026 | — | |
| 7612208 | Sep 19, 2026 | SubstanceProduct | — |
| 7612208*PED | Mar 19, 2027 | — | |
| 9006256 | Jul 27, 2027 | U-1695 |
Company
E
Eisai
China - Liaoning